Bioprinting 3D skin for patient-specific drug discovery in inflammatory skin diseases.

项目摘要 银屑病是一种具有异常表皮过度增殖的炎性皮肤病， 美国人口。目前尚无可靠的体外模型来评价银屑病药物的疗效和安全性 候选人可以进行测试。为了满足这一主要的未满足的制药需求，我们将联合收割机iPSC 重新编程和3D生物打印技术来构建3D皮肤模型，以筛选治疗这种疾病的药物。 疾病将使用iPSC方法，因为iPSC具有无限的增殖潜力， 分化成不同细胞谱系的能力，这使我们能够规避由细胞分化所施加的限制。 可以从患者获得的原代细胞的有限可用性。我们成功构建了3D皮肤 专门使用iPSC衍生的细胞（成纤维细胞和角质形成细胞），证明了这种方法的可行性。 approach. 3D生物打印可以让我们重复地构建复杂的结构，以重现人类 组织/器官。在这个项目中，我们将首先用原代角质形成细胞构建免疫活性的3D皮肤， 成纤维细胞和T细胞。然后，iPSC将从正常人获得的成纤维细胞或血细胞重新编程。 和银屑病患者。角质形成细胞和成纤维细胞将从iPSC分化用于构建3D 皮肤模型，而T细胞的丰富可用性使我们能够直接使用来自主要来源的细胞。 生物打印的银肩病特异性iPSC衍生的皮肤构建体将用于疾病建模， 药理学验证CRISPR技术将用于在iPSC衍生的细胞中整合荧光报告基因。 角质形成细胞来监测银屑病的疾病诱导和药物治疗的效果。完成本项目 将为我们提供可靠的3D生物打印模型来开发治疗银屑病的药物。此外，我们的3D皮肤 该模型可以很容易地调整和修改，以筛选治疗其他皮肤疾病的药物， approach.

Project Summary Psoriasis is an inflammatory skin disorder with abnormal epidermal hyperproliferation, which affects 2-3 % of the US population. There are no reliable in vitro models with which the efficacy and safety of psoriasis drug candidates can be tested. To meet this major unmet pharmaceutical need, we will combine iPSC reprograming and 3D bioprinting technologies to construct a 3D skin model to screen for drugs to treat this disease. iPSC methodology will be used, because iPSCs have unlimited proliferation potential and the capability to differentiate into different cell lineages, which allows us to circumvent the limitation imposed by the limited availability of primary cells that can be procured from patients. We successfully constructed 3D skin using exclusively iPSC-derived cells (fibroblasts and keratinocytes), demonstrating the feasibility of this approach. 3D bioprinting can allow us to reproducibly construct complex structures to recapitulate human tissues/organs. In this project, we will first construct immunocompetent 3D skin with primary keratinocytes, fibroblasts and T cells. Then, iPSCs will be reprogramed from fibroblasts or blood cells obtained from normal and psoriatic individuals. Keratinocytes and fibroblasts will be differentiated from iPSCs for construction of 3D skin models, whereas the abundant availability of T cells allows us to use cells directly from primary sources. Bioprinted psoriasis-specific iPSC derived skin constructs will be used for disease modeling and pharmacological validation. CRISPR technology will be used to integrate fluorescent reporters in iPSC-derived keratinocytes to monitor disease induction of psoriasis and effect of drug treatment. Completion of this project will provide us with a reliable 3D bioprinted model to develop drugs to treat psoriasis. Moreover, our 3D skin model can be easily adapted and modified to screen for drugs to treat other skin diseases, using a platform approach.